1
|
Liu P, Yao M, Gong Y, Song Y, Chen Y, Ye Y, Liu X, Li F, Dong H, Meng R, Chen H, Zheng A. Benchmarking the Human Leukocyte Antigen Typing Performance of Three Assays and Seven Next-Generation Sequencing-Based Algorithms. Front Immunol 2021; 12:652258. [PMID: 33868290 PMCID: PMC8045758 DOI: 10.3389/fimmu.2021.652258] [Citation(s) in RCA: 14] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/12/2021] [Accepted: 03/03/2021] [Indexed: 11/13/2022] Open
Abstract
With the great progress made recently in next generation sequencing (NGS) technology, sequencing accuracy and throughput have increased, while the cost for data has decreased. Various human leukocyte antigen (HLA) typing algorithms and assays have been developed and have begun to be used in clinical practice. In this study, we compared the HLA typing performance of three HLA assays and seven NGS-based HLA algorithms and assessed the impact of sequencing depth and length on HLA typing accuracy based on 24 benchmarked samples. The algorithms HISAT-genotype and HLA-HD showed the highest accuracy at both the first field and the second field resolution, followed by HLAscan. Our internal capture-based HLA assay showed comparable performance with whole exome sequencing (WES). We found that the minimal depth was 100X for HISAT-genotype and HLA-HD to obtain more than 90% accuracy at the third field level. The top three algorithms were quite robust to the change of read length. Thus, we recommend using HISAT-genotype and HLA-HD for NGS-based HLA genotyping because of their higher accuracy and robustness to read length. We propose that a minimal sequence depth for obtaining more than 90% HLA typing accuracy at the third field level is 100X. Besides, targeting capture-based NGS HLA typing may be more suitable than WES in clinical practice due to its lower sequencing cost and higher HLA sequencing depth.
Collapse
Affiliation(s)
- Ping Liu
- Department of Oncology, The Second Xiangya Hospital of Central South University, Changsha, China
| | - Minya Yao
- The First Affiliated Hospital of Zhejiang University, School of Medicine, Hangzhou, China
| | - Yu Gong
- Department of Urology, Second Affiliated Hospital, Zhejiang University College of Medicine, Hangzhou, China
| | - Yunjie Song
- The Bioinformatics Department, 3DMed Inc., Shanghai, China
| | - Yanan Chen
- The Bioinformatics Department, 3DMed Inc., Shanghai, China
| | - Yizhou Ye
- The Bioinformatics Department, 3DMed Inc., Shanghai, China
| | - Xiao Liu
- The Bioinformatics Department, 3DMed Inc., Shanghai, China
| | - Fugen Li
- The Bioinformatics Department, 3DMed Inc., Shanghai, China
| | - Hua Dong
- The Bioinformatics Department, 3DMed Inc., Shanghai, China
| | - Rui Meng
- Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
| | - Hao Chen
- The Bioinformatics Department, 3DMed Inc., Shanghai, China
| | - Aiwen Zheng
- Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Hangzhou, China.,Institute of Cancer and Basic Medicine (IBMC), Chinese Academy of Sciences, Hangzhou, China
| |
Collapse
|
2
|
Louthrenoo W, Kasitanon N, Pathanapitoon K, Wangkaew S, Kuwata S, Nishi A, Kaburaki T, Tanaka R, Takeuchi F. Contribution of HLA-B*51:01 and -A*26:01 to Behçet's disease and their clinical association in Thai patients. Int J Rheum Dis 2020; 23:247-255. [PMID: 31944588 DOI: 10.1111/1756-185x.13785] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/23/2019] [Revised: 11/30/2019] [Accepted: 12/16/2019] [Indexed: 11/29/2022]
Abstract
AIMS To investigate susceptible human leukocyte antigen (HLA) alleles and their associations with clinical features in Thai patients with Behçet's disease (BD). METHOD Eighteen HLA-A and 36 HLA-B alleles were determined in 42 Thai BD patients and 99 healthy controls (HCs) by reverse line blot assay, and reconfirmed by MICRO SSP assay. RESULTS The BD patients had significantly higher allele frequency (AF) of HLA-B*51 than the HCs (13.10% vs 5.05%, P = .025). The AF of HLA-A*26, -A*26:01 and -B*51:01 also was higher and almost reached statistical significance (5.59% vs 1.52%, P = .054, 5.95% vs 1.52%, P = .054 and 10.71% vs 4.04%, P = .051, respectively). However, the BD patients had significantly higher AF of either HLA-A*26:01 or -B*51:01 (16.67% vs 5.56%, P = .005), or -A*26:01 or -B*51X (19.05% vs 6.56%, P = .003). The AF of HLA-B*51:01 and -B*51X increased significantly in -A*26:01 non-carrier BD patients (12.16% vs 4.17%, P = .024 and 14.86% vs 5.21%, P = .019, respectively); and that of HLA-A*26:01 was significantly higher in -B*51X non-carrier BD patients (7.58% vs 1.67%, P = .034). HLA-B*51:01 associated significantly with the presence of posterior uveitis and visual impairment (18.18% vs 2.50%, P = .031 for both conditions). HLA-B*51:01 was not observed in BD patients with gastrointestinal involvement or arthritis. Furthermore, the AF of HLA-B*51:01 was significantly higher in HLA-A*26:01 non-carrier BD patients without arthritis (17.30% vs 0%, P = .050). CONCLUSION HLA-B*51:01 was a susceptible allele for Thai BD patients, and associated with posterior uveitis and visual impairment. HLA-A*26:01 was another susceptible allele in HLA-B*51X non-carrier patients. The protective effect of HLA-B*51:01 on arthritis needs further investigation.
Collapse
Affiliation(s)
- Worawit Louthrenoo
- Division of Rheumatology, Department of Internal Medicine, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand
| | - Nuntana Kasitanon
- Division of Rheumatology, Department of Internal Medicine, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand
| | - Kessara Pathanapitoon
- Department of Ophthalmology, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand
| | - Suparaporn Wangkaew
- Division of Rheumatology, Department of Internal Medicine, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand
| | - Shoji Kuwata
- Department of Internal Medicine, Faculty of Medicine, Teikyo University School of Medicine, Ichihara, Japan
| | - Ai Nishi
- Department of Ophthalmology, The University of Tokyo Hospital, Tokyo, Japan
| | - Toshikatsu Kaburaki
- Department of Ophthalmology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan
| | - Rie Tanaka
- Department of Ophthalmology, The University of Tokyo Hospital, Tokyo, Japan
| | - Fujio Takeuchi
- Department of Internal Medicine (Allergy and Rheumatology), Faculty of Medicine, University of Tokyo, Tokyo, Japan
| |
Collapse
|
3
|
Chai SJ, Yap YY, Foo YC, Yap LF, Ponniah S, Teo SH, Cheong SC, Patel V, Lim KP. Identification of Four-Jointed Box 1 (FJX1)-Specific Peptides for Immunotherapy of Nasopharyngeal Carcinoma. PLoS One 2015; 10:e0130464. [PMID: 26536470 PMCID: PMC4633155 DOI: 10.1371/journal.pone.0130464] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/12/2015] [Accepted: 05/20/2015] [Indexed: 01/02/2023] Open
Abstract
Nasopharyngeal carcinoma (NPC) is highly prevalent in South East Asia and China. The poor outcome is due to late presentation, recurrence, distant metastasis and limited therapeutic options. For improved treatment outcome, immunotherapeutic approaches focusing on dendritic and autologous cytotoxic T-cell based therapies have been developed, but cost and infrastructure remain barriers for implementing these in low-resource settings. As our prior observations had found that four-jointed box 1 (FJX1), a tumor antigen, is overexpressed in NPCs, we investigated if short 9-20 amino acid sequence specific peptides matching to FJX1 requiring only intramuscular immunization to train host immune systems would be a better treatment option for this disease. Thus, we designed 8 FJX1-specific peptides and implemented an assay system to first, assess the binding of these peptides to HLA-A2 molecules on T2 cells. After, ELISPOT assays were used to determine the peptides immunogenicity and ability to induce potential cytotoxicity activity towards cancer cells. Also, T-cell proliferation assay was used to evaluate the potential of MHC class II peptides to stimulate the expansion of isolated T-cells. Our results demonstrate that these peptides are immunogenic and peptide stimulated T-cells were able to induce peptide-specific cytolytic activity specifically against FJX1-expressing cancer cells. In addition, we demonstrated that the MHC class II peptides were capable of inducing T-cell proliferation. Our results suggest that these peptides are capable of inducing specific cytotoxic cytokines secretion against FJX1-expressing cancer cells and serve as a potential vaccine-based therapy for NPC patients.
Collapse
Affiliation(s)
- San Jiun Chai
- Cancer Research Initiatives Foundation (CARIF), Sime Darby Medical Centre, Subang Jaya, Selangor, Malaysia
| | - Yoke Yeow Yap
- Department of Surgery, Clinical Campus Faculty of Medicine and Health Sciences, Universiti Putra Malaysia, Hospital Kuala Lumpur, Kuala Lumpur, Malaysia
| | - Yoke Ching Foo
- Department of Oncology, Sime Darby Medical Centre, Subang Jaya, Selangor, Malaysia
| | - Lee Fah Yap
- Cancer Research Initiatives Foundation (CARIF), Sime Darby Medical Centre, Subang Jaya, Selangor, Malaysia
| | - Sathibalan Ponniah
- Department of Surgery, Cancer Vaccine Development Program, Uniformed Services University of the Health Sciences, Bethesda, Maryland, United States of America
| | - Soo Hwang Teo
- Cancer Research Initiatives Foundation (CARIF), Sime Darby Medical Centre, Subang Jaya, Selangor, Malaysia
| | - Sok Ching Cheong
- Cancer Research Initiatives Foundation (CARIF), Sime Darby Medical Centre, Subang Jaya, Selangor, Malaysia
| | - Vyomesh Patel
- Cancer Research Initiatives Foundation (CARIF), Sime Darby Medical Centre, Subang Jaya, Selangor, Malaysia
| | - Kue Peng Lim
- Cancer Research Initiatives Foundation (CARIF), Sime Darby Medical Centre, Subang Jaya, Selangor, Malaysia
- * E-mail:
| |
Collapse
|
4
|
Li Y, Zhou W, Du J, Jiang C, Xie X, Xue T, He Y. Generation of cytotoxic T lymphocytes specific for native or modified peptides derived from the epidermal growth factor receptor pathway substrate 8 antigen. Cancer Immunol Immunother 2015; 64:259-69. [PMID: 25376540 PMCID: PMC11028780 DOI: 10.1007/s00262-014-1631-y] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/24/2013] [Accepted: 10/23/2014] [Indexed: 10/24/2022]
Abstract
The ideal tumor antigen for the development of a cancer immunotherapy is one that is expressed only in tumor cells. The epidermal growth factor receptor pathway substrate 8 gene (Eps8) might be an effective antigen for cancer immunotherapy as it is overexpressed in a variety of cancer cells but not in normal tissues. In this study, the potential utility of an Eps8-derived immunotherapy was tested in vitro and in vivo. Three computer-based algorithms were used to design eight Eps8 native epitopes with potentially high binding affinity to the HLA-A2.1 molecule, which is found at a high frequency in the Chinese population. Of these eight, three peptides with a moderate affinity to the HLA-A2.1 molecule were modified at anchor residue positions to achieve stronger immunogenicity. These four modified peptides displayed stronger binding affinity to HLA-A2.1 molecules on T2 cells and a lower dissociation rate. In functional assays with human PBMCs in vitro and in HLA-A2.1/K(b) transgenic mice in vivo, CTLs primed by each native and modified peptide secreted IFN-γ and were toxic to cancer cells from a variety of tissue types in an HLA-A2.1-restricted and Eps8-specific manner. p101-109-2L and p276-284-1Y9V were superior to other modified and native epitopes both in vitro and in vivo. These results indicate that employing the native and modified epitopes identified here in Eps8-based immunotherapy for HLA-A2.1 positive cancer patients may result in efficient anticancer immune responses for diverse tumor types.
Collapse
MESH Headings
- Adaptor Proteins, Signal Transducing/chemistry
- Adaptor Proteins, Signal Transducing/immunology
- Amino Acid Sequence
- Animals
- Cell Line
- Cell Line, Tumor
- Cytotoxicity, Immunologic
- Epitopes, T-Lymphocyte/chemistry
- Epitopes, T-Lymphocyte/immunology
- Epitopes, T-Lymphocyte/metabolism
- HLA-A2 Antigen/immunology
- HLA-A2 Antigen/metabolism
- Humans
- Mice
- Mice, Transgenic
- Peptides/chemistry
- Peptides/immunology
- Peptides/metabolism
- Protein Binding
- Protein Stability
- T-Cell Antigen Receptor Specificity/immunology
- T-Lymphocytes, Cytotoxic/immunology
- T-Lymphocytes, Cytotoxic/metabolism
Collapse
Affiliation(s)
- Yuhua Li
- Department of Hematology, Zhujiang Hospital, Southern Medical University, No. 253 GongyeDadaoZhong, Guangzhou, Guangdong People’s Republic of China
| | - Weijun Zhou
- Department of Hematology, Zhujiang Hospital, Southern Medical University, No. 253 GongyeDadaoZhong, Guangzhou, Guangdong People’s Republic of China
| | - Jingwen Du
- Department of Hematology, Zhujiang Hospital, Southern Medical University, No. 253 GongyeDadaoZhong, Guangzhou, Guangdong People’s Republic of China
| | - Chunjun Jiang
- Department of Hematology, Zhujiang Hospital, Southern Medical University, No. 253 GongyeDadaoZhong, Guangzhou, Guangdong People’s Republic of China
| | - Xiaoling Xie
- Department of Hematology, Zhujiang Hospital, Southern Medical University, No. 253 GongyeDadaoZhong, Guangzhou, Guangdong People’s Republic of China
| | - Tongyuan Xue
- Department of Hematology, Zhujiang Hospital, Southern Medical University, No. 253 GongyeDadaoZhong, Guangzhou, Guangdong People’s Republic of China
| | - Yanjie He
- Department of Hematology, Zhujiang Hospital, Southern Medical University, No. 253 GongyeDadaoZhong, Guangzhou, Guangdong People’s Republic of China
| |
Collapse
|
5
|
Tada Y, Yoshikawa T, Shimomura M, Sawada Y, Sakai M, Shirakawa H, Nobuoka D, Nakatsura T. Analysis of cytotoxic T lymphocytes from a patient with hepatocellular carcinoma who showed a clinical response to vaccination with a glypican‑3‑derived peptide. Int J Oncol 2013; 43:1019-26. [PMID: 23903757 PMCID: PMC3829797 DOI: 10.3892/ijo.2013.2044] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/03/2013] [Accepted: 07/12/2013] [Indexed: 12/21/2022] Open
Abstract
Glypican-3 (GPC3), which is a carcinoembryonic antigen, is overexpressed in human hepatocellular carcinoma (HCC). Previously, we performed a phase I clinical trial of GPC3-derived peptide vaccination in patients with advanced HCC, and reported that GPC3 peptide vaccination is safe and has clinical efficacy. Moreover, we proposed that a peptide-specific CTL response is a predictive marker of overall survival in patients with HCC who receive peptide vaccination. In this study, we established GPC3-derived peptide-specific CTL clones from the PBMCs of an HLA-A
*
02:07-positive patient with HCC who was vaccinated with an HLA-A2-restricted GPC3 peptide vaccine and showed a clinical response in the phase I clinical trial. Established CTL clones were analyzed using the IFN-γ ELISPOT assay and a cytotoxicity assay. GPC3 peptide-specific CTL clones were established successfully from the PBMCs of the patient. One CTL clone showed cytotoxicity against cancer cell lines that expressed endogenously the GPC3 peptide. The results suggest that CTLs have high avidity, and that natural antigen-specific killing activity against tumor cells can be induced in a patient with HCC who shows a clinical response to vaccination with the GPC3
144–152
peptide.
Collapse
Affiliation(s)
- Yoshitaka Tada
- Division of Cancer Immunotherapy, Research Center for Innovative Oncology, National Cancer Center Hospital East, Kashiwa, Chiba 277‑8577, Japan
| | | | | | | | | | | | | | | |
Collapse
|
6
|
The design and proof of concept for a CD8(+) T cell-based vaccine inducing cross-subtype protection against influenza A virus. Immunol Cell Biol 2012; 91:96-104. [PMID: 23146941 DOI: 10.1038/icb.2012.54] [Citation(s) in RCA: 30] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/06/2023]
Abstract
In this study, we examined the reactivity of human peripheral blood mononuclear cells to a panel of influenza A virus (IAV) CD8(+) T-cell epitopes that are recognised by the major human leukocyte antigen (HLA) groups represented in the human population. We examined the level of recognition in a sample of the human population and the potential coverage that could be achieved if these were incorporated into a T-cell epitope-based vaccine. We then designed a candidate influenza vaccine that incorporated three of the examined HLA-A2-restricted influenza epitopes into Pam2Cys-based lipopeptides. These lipopeptides do not require the addition of an adjuvant and can be delivered directly to the respiratory mucosa enabling the generation of local memory cell populations that are crucial for clearance of influenza. Intranasal administration of a mixture of three lipopeptides to HLA-A2 transgenic HHD mice elicited multiple CD8(+) T-cell specificities in the spleen and lung that closely mimicked the response generated following natural infection with influenza. These CD8(+) T cells were associated with viral reduction following H3N1 influenza virus challenge for as long as 3 months after lipopeptide administration. In addition, lipopeptides containing IAV-targeting epitopes conferred substantial benefit against death following infection with a virulent H1N1 strain. Because CD8(+) T cell epitopes are often derived from highly conserved regions of influenza viruses, such vaccines need not be reformulated annually and unlike current antibody-inducing vaccines could provide cross-protective immunity against newly emerging pandemic viruses.
Collapse
|
7
|
Donaldson CD, Jack RH, Møller H, Lüchtenborg M. Oral cavity, pharyngeal and salivary gland cancer: Disparities in ethnicity-specific incidence among the London population. Oral Oncol 2012; 48:799-802. [DOI: 10.1016/j.oraloncology.2012.03.005] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/20/2011] [Revised: 03/06/2012] [Accepted: 03/08/2012] [Indexed: 10/28/2022]
|
8
|
Liu Q, Zheng Y, Yu Y, Tan Q, Huang X. Identification of HLA-A*0201-restricted CD8+ T-cell epitope C₆₄₋₇₂ from hepatitis B virus core protein. Int Immunopharmacol 2012; 13:141-7. [PMID: 22480777 DOI: 10.1016/j.intimp.2012.03.018] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/06/2012] [Revised: 03/20/2012] [Accepted: 03/20/2012] [Indexed: 12/22/2022]
Abstract
The efficacy of a potential therapeutic vaccine against chronic hepatitis B virus (HBV) infection depends on the development of strong and multi-specific T cell responses. The potency of CD8+ cytotoxic T lymphocyte (CTL) responses toward HBV core antigen (HBcAg) has been shown to be critical for the outcomes of HBV chronic infection. In this study we have identified a previously undescribed HLA-A*0201-restricted HBcAg-specific CTL epitope (HBcAg₆₄₋₇₂, C₆₄₋₇₂, ELMTLATWV). T2 binding assay showed that C₆₄₋₇₂ had high affinity to HLA-A*0201 molecule. Functionally, the peptide C₆₄₋₇₂ could induce peptide-specific CTLs both in vivo (HLA-A2.1/K(b) transgenic mice) and in vitro (PBLs of healthy HLA-A2.1+ donors), as demonstrated by interferon-γ (IFN-γ) secretion upon stimulation with C₆₄₋₇₂-pulsed T2 cells or autologous human dendritic cells (DCs) respectively. HLA-A*0201-C₆₄₋₇₂ tetramer staining revealed the presence of a significant population of C₆₄₋₇₂-specific CTLs in C₆₄₋₇₂-stimulated CD8+ T cells. Furthermore, the peptide-specific cytotoxic reactivity and the production of perforin and granzyme B of CTLs also increased after stimulation with C₆₄₋₇₂-pulsed autologous DCs. These results indicate that the newly identified epitope C₆₄₋₇₂ has potential to be used in the development of immunotherapeutic approaches to HBV infection.
Collapse
Affiliation(s)
- Qiuyan Liu
- National Key Laboratory of Medical Immunology & Institute of Immunology, Second Military Medical University, Shanghai, China.
| | | | | | | | | |
Collapse
|
9
|
Roomp K, Domingues FS. Predicting interactions between T cell receptors and MHC-peptide complexes. Mol Immunol 2010; 48:553-62. [PMID: 21106246 DOI: 10.1016/j.molimm.2010.10.014] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/22/2010] [Accepted: 10/24/2010] [Indexed: 12/30/2022]
Abstract
Conserved interactions between T cell receptors (TCRs) and major histocompatibility complex (MHC) proteins with bound peptide antigens are not well understood. In order to gain a better understanding of the interaction modes of human TCR variable (V) regions, we have performed a structural analysis of the TCRs bound to their MHC-peptide ligands in human, using the available structural models determined by X-ray crystallography. We identified important differences to previous studies in which such interactions were evaluated. Based on the interactions found in the actual experimental structures we developed the first rule-based approach for predicting the ability of TCR residues in the complementarity-determining region (CDR) 1, CDR2, and CDR3 loops to interact with the MHC-peptide antigen complex. Two relatively simple algorithms show good performance under cross validation.
Collapse
Affiliation(s)
- Kirsten Roomp
- Department of Computational Biology and Applied Algorithmics, Max Planck Institute for Informatics, 66123 Saarbruecken, Germany.
| | | |
Collapse
|
10
|
Identification of an HLA-A*0201-restricted CD8+ T-cell epitope encoded within Leptospiral immunoglobulin-like protein A. Microbes Infect 2010; 12:364-73. [DOI: 10.1016/j.micinf.2010.01.010] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/10/2009] [Revised: 01/20/2010] [Accepted: 01/20/2010] [Indexed: 11/24/2022]
|
11
|
Li F, Yang D, Wang Y, Liu B, Deng Y, Wang L, Shang X, Tong W, Ni B, Wu Y. Identification and modification of an HLA-A*0201-restricted cytotoxic T lymphocyte epitope from Ran antigen. Cancer Immunol Immunother 2009; 58:2039-49. [PMID: 19430788 PMCID: PMC11030261 DOI: 10.1007/s00262-009-0712-9] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/26/2009] [Accepted: 04/14/2009] [Indexed: 11/25/2022]
Abstract
Ran is considered to be a promising target for tumor-specific immunotherapy because its protein is exclusively expressed in tumor tissues, though its mRNA can be expressed in most normal tissues. In our study, we obtained four candidate wild-type epitopes designated Ran1, Ran2, Ran3, and Ran4, derived from the Ran antigen with the highest predicted affinity with MHC-I, indicated by affinity prediction plots and molecular dynamics simulation. However, in vitro affinity assays of these epitopes showed only a moderate affinity with MHC-I. Thus, we designed altered peptide ligands (APLs) derived from Ran wild-type epitopes with preferred primary and auxiliary HLA-A*0201 molecule anchor residue replacement. Of the eight tested peptides, the 1Y analog had the strongest binding-affinity and lowest-dissociation rate to HLA-A*0201. Additionally, we investigated the CTLs activities induced by Ran wild-type peptides and the APLs in human PBMCs and in HLA-A*0201/K(b) transgenic mice. Ran1 1Y was superior to other APLs and wild-type peptides in eliciting epitope-specific CTL immune responses both in vitro and in vivo. In summary, a wild-type epitope of the tumor-specific antigen Ran, expressed broadly in many tumors, was identified and designated Ran1. An APL of Ran1, Ran1 1Y, was further designed and verified in vitro and in vivo and found to elicit a stronger Ran-specific CTL response, indicating a potential anti-tumor application in the future.
Collapse
Affiliation(s)
- Fan Li
- Department of Immunology, Institute of Immunology, Third Military Medical University, 400038 Chongqing, China
- Department of General Surgery, Institute of Surgery Research, Daping Hospital, Third Military Medical University, 400042 Chongqing, China
| | - Di Yang
- Department of Immunology, Institute of Immunology, Third Military Medical University, 400038 Chongqing, China
| | - Yiqin Wang
- Department of Immunology, Institute of Immunology, Third Military Medical University, 400038 Chongqing, China
- Department of Nephrology, Xinqiao Hospital, Third Military Medical University, 400037 Chongqing, China
| | - Baohua Liu
- Department of General Surgery, Institute of Surgery Research, Daping Hospital, Third Military Medical University, 400042 Chongqing, China
| | - Yijing Deng
- Department of Immunology, Institute of Immunology, Third Military Medical University, 400038 Chongqing, China
- Department of Geriatric Gastroenterology, Chinese PLA General Hospital, 28 FuXing Street, 100853 Beijing, China
| | - Li Wang
- Department of Immunology, Institute of Immunology, Third Military Medical University, 400038 Chongqing, China
| | - Xiaoyun Shang
- Department of Immunology, Institute of Immunology, Third Military Medical University, 400038 Chongqing, China
| | - Weidong Tong
- Department of General Surgery, Institute of Surgery Research, Daping Hospital, Third Military Medical University, 400042 Chongqing, China
| | - Bing Ni
- Department of Immunology, Institute of Immunology, Third Military Medical University, 400038 Chongqing, China
| | - Yuzhang Wu
- Department of Immunology, Institute of Immunology, Third Military Medical University, 400038 Chongqing, China
| |
Collapse
|
12
|
Wei J, Li J, Zhang X, Tang Y, Wang J, Wu Y. A Naturally Processed Epitope on Rotavirus VP7 Glycoprotein Recognized by HLA-A2.1-Restricted Cytotoxic CD8+T Cells. Viral Immunol 2009; 22:189-94. [DOI: 10.1089/vim.2008.0091] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Affiliation(s)
- Jing Wei
- Institute of Immunology, Third Military Medical University, District Shapingba, Chongqing, People's Republic of China
- Key Laboratory of Aquatic Organism Reproduction and Development (Ministry of Education), Southwest University, Chongqing, People's Republic of China
| | - Jintao Li
- Institute of Immunology, Third Military Medical University, District Shapingba, Chongqing, People's Republic of China
| | - Xiaoping Zhang
- Key Laboratory of Aquatic Organism Reproduction and Development (Ministry of Education), Southwest University, Chongqing, People's Republic of China
| | - Yan Tang
- Institute of Immunology, Third Military Medical University, District Shapingba, Chongqing, People's Republic of China
| | - Jingxue Wang
- Institute of Immunology, Third Military Medical University, District Shapingba, Chongqing, People's Republic of China
| | - Yuzhang Wu
- Institute of Immunology, Third Military Medical University, District Shapingba, Chongqing, People's Republic of China
| |
Collapse
|
13
|
Xu DH, Zhou CH, Xia YP, Qiu ZY, Wu YZ, Jia ZC, Zhou W. Cytotoxic T lymphocyte response induced by an improved synthetic lipopeptide vaccine against cervical cancer. Acta Pharmacol Sin 2007; 28:695-702. [PMID: 17439726 DOI: 10.1111/j.1745-7254.2007.00538.x] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/21/2022] Open
Abstract
AIM To explore cytotoxic T lymphocyte (CTL) response induced by the lipopeptide vaccine against cervical cancer. METHODS The immunological effect inducing CD8+ T cell-mediated cytotoxicity was investigated in human leukocyte antigen (HLA)-A2 transgenic mice and peripheral blood mononuclear cells (PBMC) of healthy HLA-A2.1+blood donor. The activity of specific CTL was measured by using a standard 4 h( 51)Cr release assay. The content of major histocompatibility complex (MHC) I on T2 cells and the expression of immune molecules on dendritic cells (DC) were detected by flow cytometry, and the concentrations of interleukin (IL)-12 and interferon-gamma were determined by ELISA. RESULTS The lipopeptide induced a strong epitope-specific CTL response both in vivo (transgenic mice) and in vitro (human PBMC). This CTL induction was critically dependent on the presence of the helper T lymphocyte epitope in transgenic mice, and the presence of a lipid tail bypassed the need for an adjuvant. The stability and persistence of the antigenic complex formed with the lipopeptide increased in comparison with the CTL parental peptide. The lipopeptide could induce the production of IL-12 in DC, but not the maturation of DC directly. CONCLUSION The combination of CTL and the T helper epitope and lipid molecule can remarkably improve the immunogenicity of the CTL peptide, the mechanism of which is associated with an increase in the stability and persistence of the antigenic complex formed with the lipopeptide and in the production of IL-12 in DC induced by the lipopeptide. The lipopeptide can be considered a more effective vaccine type for human being.
Collapse
Affiliation(s)
- Dao-Hua Xu
- Department of Pharmacology, Guangdong Medical College, Zhanjiang 524023, China.
| | | | | | | | | | | | | |
Collapse
|
14
|
Han JF, Zhao TT, Liu HL, Lin ZH, Wang HM, Ruan ZH, Zou LY, Wu YZ. Identification of a new HLA-A*0201-restricted cytotoxic T lymphocyte epitope from CML28. Cancer Immunol Immunother 2006; 55:1575-83. [PMID: 16534571 PMCID: PMC11031099 DOI: 10.1007/s00262-006-0152-8] [Citation(s) in RCA: 17] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/15/2006] [Accepted: 02/27/2006] [Indexed: 02/07/2023]
Abstract
Identification of cytotoxic T lymphocyte (CTL) epitopes from additional tumor antigens is essential for the development of specific immunotherapy of malignant tumors. CML28, a recently discovered cancer-testis (CT) antigen from chronic myelogenous leukemia, is considered to be a promising target of tumor-specific immunotherapy. Because HLA-A*0201 is one of the most common histocompatibility molecule in Chinese, we aim at identifying CML28 peptides presented by HLA-A*0201. A panel of CML28-derived antigenic peptides was predicted using a computer-based program. Four peptides with highest predicted score were synthesized and tested for their binding affinities to HLA-A*0201 molecule. Then these peptides were assessed for their immunogenicity to elicit specific immune responses mediated by CTLs both in vitro, from PBMCs sourced from four healthy HLA-A*0201(+) donors, and in vivo, in HLA-A*0201 transgenic mice. One of the tested peptides, CML28((173-181)), induced peptide-specific CTLs in vitro as well as in vivo, which could specifically secrete IFN-gamma and lyse major histocompatibility complex (MHC)-matched tumor cell lines endogenously expressing CML28 antigen and CML28((173-181) )pulsed Jurkat-A2/Kb cells, respectively. These results demonstrate that CML28((173-181) )is a naturally processed and presented CTL epitope with HLA-A*0201 motif and has a promising immunogenicity both in vitro and in vivo. As CML28 is expressed in a large variety of histological tumors besides chronic myelogenous leukemia, we propose that the newly identified epitope, CML28((173-181)), would be of potential use in peptide-based, cancer-specific immunotherapy against a broad spectrum of tumors.
Collapse
MESH Headings
- Amino Acid Sequence
- Animals
- Antigen Presentation/immunology
- Antigens, Neoplasm/genetics
- Antigens, Neoplasm/immunology
- Antigens, Neoplasm/pharmacology
- Antigens, Surface/genetics
- Antigens, Surface/immunology
- Antigens, Surface/pharmacology
- COS Cells
- Cell Line, Tumor
- Chlorocebus aethiops
- Epitopes, T-Lymphocyte/immunology
- Exoribonucleases/genetics
- Exoribonucleases/immunology
- Exoribonucleases/pharmacology
- Exosome Multienzyme Ribonuclease Complex
- HLA-A Antigens/metabolism
- HLA-A2 Antigen
- Humans
- Mice
- Mice, Transgenic
- Molecular Sequence Data
- Neoplasms/immunology
- Peptides/genetics
- Peptides/immunology
- Peptides/pharmacology
- RNA-Binding Proteins
- T-Lymphocytes, Cytotoxic/drug effects
- T-Lymphocytes, Cytotoxic/immunology
Collapse
Affiliation(s)
- Jun-Feng Han
- Institute of Immunology, Third Military Medical University, 30 Gaotanyan Street, Shapingba District, 400038 Chongqing, China
| | - Ting-Ting Zhao
- Institute of Immunology, Third Military Medical University, 30 Gaotanyan Street, Shapingba District, 400038 Chongqing, China
| | - Hong-Li Liu
- Institute of Immunology, Third Military Medical University, 30 Gaotanyan Street, Shapingba District, 400038 Chongqing, China
| | - Zhi-Hua Lin
- Institute of Immunology, Third Military Medical University, 30 Gaotanyan Street, Shapingba District, 400038 Chongqing, China
| | - Hui-Ming Wang
- Institute of Immunology, Third Military Medical University, 30 Gaotanyan Street, Shapingba District, 400038 Chongqing, China
| | - Zhi-Hua Ruan
- Institute of Immunology, Third Military Medical University, 30 Gaotanyan Street, Shapingba District, 400038 Chongqing, China
| | - Li-Yun Zou
- Institute of Immunology, Third Military Medical University, 30 Gaotanyan Street, Shapingba District, 400038 Chongqing, China
| | - Yu-Zhang Wu
- Institute of Immunology, Third Military Medical University, 30 Gaotanyan Street, Shapingba District, 400038 Chongqing, China
| |
Collapse
|
15
|
Wei J, Li JT, Zhang XP, Tang Y, Wang JX, Zhang B, Wu YZ. Identification of an HLA-A*0201-restricted cytotoxic T-lymphocyte epitope in rotavirus VP6 protein. J Gen Virol 2006; 87:3393-3396. [PMID: 17030875 DOI: 10.1099/vir.0.82031-0] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022] Open
Abstract
The function of cytotoxic T lymphocytes (CTLs) in rotavirus (RV) infection in humans is poorly understood. To date, no RV-specific human leukocyte antigen (HLA) class I-restricted T-cell epitopes have been described. In this study, four peptides derived from human RV Wa strain VP6 protein were predicted by computer algorithms and verified by an HLA*0201-binding assay. Two peptides with high affinity for HLA-A*0201 molecules were further assessed. The CTLs induced in vitro by P340-348 (TLLANVTAV)-loaded autologous dendritic cells from peripheral blood lymphocytes of HLA-A*0201-matched healthy donors released gamma interferon specifically upon stimulation with P340-348-loaded T2 cells. The CTLs lysed both P340-348-loaded T2 cells and human RV Wa strain-infected HLA-A*0201(+) Caco-2 cells in an antigen-specific and HLA-A*0201-restricted manner. At the same time, P340-348 was shown to be immunogenic in vivo in HLA-A*0201/Kb transgenic mice. It is proposed that P340-348 is an HLA-A*0201-restricted CTL epitope.
Collapse
Affiliation(s)
- Jing Wei
- Institute of Immunology, PLA, The Third Military Medical University, Chongqing 400038, People's Republic of China
| | - Jin-Tao Li
- Institute of Immunology, PLA, The Third Military Medical University, Chongqing 400038, People's Republic of China
| | - Xiao-Ping Zhang
- Institute of Immunology, PLA, The Third Military Medical University, Chongqing 400038, People's Republic of China
| | - Yan Tang
- Institute of Immunology, PLA, The Third Military Medical University, Chongqing 400038, People's Republic of China
| | - Jing-Xue Wang
- Institute of Immunology, PLA, The Third Military Medical University, Chongqing 400038, People's Republic of China
| | - Bei Zhang
- Institute of Immunology, PLA, The Third Military Medical University, Chongqing 400038, People's Republic of China
| | - Yu-Zhang Wu
- Institute of Immunology, PLA, The Third Military Medical University, Chongqing 400038, People's Republic of China
| |
Collapse
|
16
|
Zhou M, Xu D, Li X, Li H, Shan M, Tang J, Wang M, Wang FS, Zhu X, Tao H, He W, Tien P, Gao GF. Screening and identification of severe acute respiratory syndrome-associated coronavirus-specific CTL epitopes. THE JOURNAL OF IMMUNOLOGY 2006; 177:2138-45. [PMID: 16887973 DOI: 10.4049/jimmunol.177.4.2138] [Citation(s) in RCA: 78] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
Abstract
Severe acute respiratory syndrome (SARS) is a highly contagious and life-threatening disease that emerged in China in November 2002. A novel SARS-associated coronavirus was identified as its principal etiologic agent; however, the immunopathogenesis of SARS and the role of special CTLs in virus clearance are still largely uncharacterized. In this study, potential HLA-A*0201-restricted spike (S) and nucleocapsid protein-derived peptides were selected from an online database and screened for potential CTL epitopes by in vitro refolding and T2 cell-stabilization assays. The antigenicity of nine peptides which could refold with HLA-A*0201 molecules was assessed with an IFN-gamma ELISPOT assay to determine the capacity to stimulate CTLs from PBMCs of HLA-A2(+) SARS-recovered donors. A novel HLA-A*0201-restricted decameric epitope P15 (S411-420, KLPDDFMGCV) derived from the S protein was identified and found to localize within the angiotensin-converting enzyme 2 receptor-binding region of the S1 domain. P15 could significantly enhance the expression of HLA-A*0201 molecules on the T2 cell surface, stimulate IFN-gamma-producing CTLs from the PBMCs of former SARS patients, and induce specific CTLs from P15-immunized HLA-A2.1 transgenic mice in vivo. Furthermore, significant P15-specific CTLs were induced from HLA-A2.1-transgenic mice immunized by a DNA vaccine encoding the S protein; suggesting that P15 was a naturally processed epitope. Thus, P15 may be a novel SARS-associated coronavirus-specific CTL epitope and a potential target for characterization of virus control mechanisms and evaluation of candidate SARS vaccines.
Collapse
MESH Headings
- Animals
- Cells, Cultured
- Coronavirus Nucleocapsid Proteins
- Enzyme-Linked Immunosorbent Assay
- Epitopes, T-Lymphocyte/immunology
- Epitopes, T-Lymphocyte/isolation & purification
- Epitopes, T-Lymphocyte/metabolism
- HLA-A Antigens/biosynthesis
- HLA-A Antigens/metabolism
- HLA-A2 Antigen
- Humans
- Interferon-gamma/metabolism
- Intracellular Fluid/immunology
- Intracellular Fluid/metabolism
- Intracellular Fluid/virology
- Leukocytes, Mononuclear/immunology
- Leukocytes, Mononuclear/virology
- Lymphocyte Activation/immunology
- Membrane Glycoproteins/administration & dosage
- Membrane Glycoproteins/immunology
- Membrane Glycoproteins/isolation & purification
- Membrane Glycoproteins/metabolism
- Mice
- Mice, Transgenic
- Nucleocapsid Proteins/immunology
- Nucleocapsid Proteins/isolation & purification
- Nucleocapsid Proteins/metabolism
- Peptide Fragments/administration & dosage
- Peptide Fragments/immunology
- Peptide Fragments/isolation & purification
- Peptide Fragments/metabolism
- Protein Binding/immunology
- Severe acute respiratory syndrome-related coronavirus/immunology
- Severe acute respiratory syndrome-related coronavirus/isolation & purification
- Severe acute respiratory syndrome-related coronavirus/metabolism
- Spike Glycoprotein, Coronavirus
- T-Lymphocytes, Cytotoxic/immunology
- T-Lymphocytes, Cytotoxic/metabolism
- T-Lymphocytes, Cytotoxic/virology
- Vaccines, DNA/administration & dosage
- Vaccines, DNA/immunology
- Viral Envelope Proteins/administration & dosage
- Viral Envelope Proteins/immunology
- Viral Envelope Proteins/isolation & purification
- Viral Envelope Proteins/metabolism
Collapse
Affiliation(s)
- Minghai Zhou
- Center for Molecular Immunology and Center for Molecular Virology, Institute of Microbiology, Chinese Academy of Sciences (CAS), Beijing, The People's Republic of China
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
17
|
Zhao L, Mou DC, Leng XS, Peng JR, Wang WX, Huang L, Li S, Zhu JY. Expression of cancer-testis antigens in hepatocellular carcinoma. World J Gastroenterol 2004; 10:2034-8. [PMID: 15237429 PMCID: PMC4572328 DOI: 10.3748/wjg.v10.i14.2034] [Citation(s) in RCA: 23] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/15/2022] Open
Abstract
AIM: To investigate the expression of cancer-testis (CT) antigens MAGE-1, SSX-1 ,CTp11 and HCA587 genes in hepatocellular carcinoma (HCC) and the possibility of applying these antigens as targets for specific immunotherapy for HCC.
METHODS: Expression levels of MAGE-1, SSX-1, CTp11 and HCA587 mRNA were detected with reverse transcription polymerase chain reaction (RT-PCR) in HCC tissues and corresponding adjacent non-cancerous tissues from 105 HCC patients, 40 samples of cirrhosis and normal liver tissues. Genes of five samples with positive PCR results were sequenced.
RESULTS: Of 105 HCC tissues, MAGE1, SSX-1 ,CTp11 and HCA587 mRNA expressions were detectable in 75.2% (79/105), 72.4% (76/105), 62.9% (66/105) and 56.2% (59/105) of HCC samples, respectively. About 93.3% (98/105), 72.4% (76/105), 48.6% (51/105) and 37.1% (39/105) of HCC tissues positively expressed at least one, two, three, and four members of CT antigens, respectively. Conversely, only SSX-1 could be detectable in 2.9% (3/105) of the corresponding adjacent non-HCC tissues in which no metastatic lesion was found. Of the latter 3 patients, biopsy samples far from tumor were obtained in 2 patients and RT-PCR indicated no expression of SSX-1 mRNA in these two samples. In addition, none of 40 samples of cirrhotic and normal liver tissues expressed CT antigen gene mRNA. DNA sequences confirmed that the RT-PCR products were true target cDNA. No relationship was found between expression of CT antigens and clinico pathological indicators such as age, gender, tumor size, degree of tumor differentiation, serum α-fetoprotein level and infection of hepatitis B virus or hepatitis C virus (P > 0.05).
CONCLUSION: CT antigens genes (MAGE-1, SSX-1, CTp11 and HCA587) are expressed with high percentage and specificity in HCC and their products are promising targets for antigen-specific immunotherapy of HCC. High frequent co-expression of multiple members of CT antigens in HCC provides possibility of polyvalent vaccinations for HCC.
Collapse
Affiliation(s)
- Li Zhao
- Center of Hepatobiliary Surgery, People's Hospital, Peking University, 11 XiZhimen Nandajie, West District, Beijing 100044, China
| | | | | | | | | | | | | | | |
Collapse
|
18
|
Wang B, Chen H, Jiang X, Zhang M, Wan T, Li N, Zhou X, Wu Y, Yang F, Yu Y, Wang X, Yang R, Cao X. Identification of an HLA-A*0201-restricted CD8+ T-cell epitope SSp-1 of SARS-CoV spike protein. Blood 2004; 104:200-6. [PMID: 15016646 PMCID: PMC8254376 DOI: 10.1182/blood-2003-11-4072] [Citation(s) in RCA: 80] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/14/2023] Open
Abstract
A novel coronavirus, severe acute respiratory syndrome (SARS)–associated coronavirus (SARS-CoV), has been identified as the causal agent of SARS. Spike (S) protein is a major structural glycoprotein of the SARS virus and a potential target for SARS-specific cell-mediated immune responses. A panel of S protein–derived peptides was tested for their binding affinity to HLA-A*0201 molecules. Peptides with high affinity for HLA-A*0201 were then assessed for their capacity to elicit specific immune responses mediated by cytotoxic T lymphocytes (CTLs) both in vivo, in HLA-A2.1/Kb transgenic mice, and in vitro, from peripheral blood lymphocytes (PBLs) sourced from healthy HLA-A2.1+ donors. SARS-CoV protein-derived peptide-1 (SSp-1 RLNEVAKNL), induced peptide-specific CTLs both in vivo (transgenic mice) and in vitro (human PBLs), which specifically released interferon-γ (IFN-γ) upon stimulation with SSp-1–pulsed autologous dendritic cells (DCs) or T2 cells. SSp-1–specific CTLs also lysed major histocompatibility complex (MHC)–matched tumor cell lines engineered to express S proteins. HLA-A*0201–SSp-1 tetramer staining revealed the presence of significant populations of SSp-1–specific CTLs in SSp-1–induced CD8+ T cells. We propose that the newly identified epitope SSp-1 will help in the characterization of virus control mechanisms and immunopathology in SARS-CoV infection, and may be relevant to the development of immunotherapeutic approaches for SARS.
Collapse
Affiliation(s)
- Baomei Wang
- Institute of Immunology, Second Military Medical University, Shanghai, People's Republic of China
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|